Trial Profile
Phase II Trial of Isatuximab (SAR650984) With or Without Lenalidomide in Patients With High Risk Smoldering Multiple Myeloma (ISAMAR)
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 28 Apr 2024
Price :
$35
*
At a glance
- Drugs Isatuximab (Primary) ; Lenalidomide
- Indications Smoldering multiple myeloma
- Focus Therapeutic Use
- Acronyms ISAMAR
- 22 Apr 2024 The drug will now be tested either in combination with Lenalidomide or without Lenalidomide.
- 29 Nov 2023 Status changed from recruiting to active, no longer recruiting.
- 06 Jun 2023 Primary endpoint (Overall response ( partial response)) has been met, as per results presented at the 59th Annual Meeting of the American Society of Clinical Oncology.